NVO Earnings Prediction
The chart below shows how NVO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NVO sees a -1.34% change in stock price 10 days leading up to the earnings, and a +2.60% change 10 days following the report. On the earnings day itself, the stock moves by -0.55%. This data can give you a slight idea of what to expect for the next quarter's release.
NVO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
10.50B
22.51%
6.94%
Gross Margin
84.14%
0.81%
-0.90%
Operating Margin
47.43%
3.51%
2.04%
Net Margin
38.28%
0.03%
29.94%
EPS
0.90
23.29%
38.46%
No Data Available
NVO Earnings Analysis
Novo-Nordisk A/S Corporation (NVO.N) Earnings Conference Call
Positive
Sales and Profit Growth: In the first nine months of 2024, we delivered 24% sales growth and 22% operating profit growth, reflecting continued scaling of the company.
Patient Reach Expansion: We are now reaching around 3x more patients with our GLP-1 treatments compared to three years ago.
Patient Growth in Treatments: We are now serving more than 43 million patients with our diabetes and obesity treatments, an increase of almost 3 million patients compared to 12 months ago.
Sales Growth Overview: Our total sales increased by 24% driven by both operating units, with North American operations growing 31% and international operations growing 15%.
GLP-1 Sales Surge: Our GLP-1 sales in diabetes increased by 26%, driven by North American operations growing 32% and international operations growing 16%.
Negative
Carbon Emissions Increase: Our total carbon emissions rose by 34% compared to the first nine months of 2023. This was primarily driven by our increased investments in capital expenditure to meet the high demand of our treatments.
Sales Growth and Challenges: Our total sales increased by 24% in the first nine months of 2024, but this growth was offset by supply constraints and related drug shortages across a number of products and geographies.
Sales and Distribution Cost Increase: Sales and distribution costs increased by 10% in both Danish kroner and at constant exchange rates, reflecting promotional activities related to Wegovy, while in international operations, the increase is mainly related to obesity care market development activities.
R&D Cost Surge: Research and development costs increased by 56%, both measured in Danish kroner and at constant exchange rates, reflecting increased late-stage clinical trial activity and increased early research activities as well as the impairment loss related to intangible assets, including ocedurinone at DKK 5.7 billion.
Free Cash Flow Comparison: Free cash flow realized in 2024 was DKK 71.8 billion compared to DKK 75.6 billion in the first nine months of 2023, reflecting increasing capital expenditure partly countered by net cash generated from operating activities.
NVO FAQs
How does NVO typically perform around its earnings report dates?
Is Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NVO Earning Call Sentiment
Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
NVO.N
-0.52%Positive
The earnings call reveals strong sales and operating profit growth, a slight gross margin increase, and an optimistic sales growth outlook. However, concerns about regulatory risks, increased competition, and a significant impairment loss slightly temper the outlook. The Q&A section shows confidence in future growth, despite some uncertainties about product timelines. The share buyback program and raised guidance further support a positive sentiment. Overall, the positive financial performance and optimistic guidance outweigh the risks, suggesting a positive stock price movement in the near term.